Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)

This study (Atezomeso) tests whether atezolizumab (an immunotherapy drug) given after surgery and chemotherapy reduces the chance of mesothelioma (a cancer of the lining of the lung) coming back in patients whose tumors were completely removed. **You may be eligible if...** - You have confirmed malignant pleural mesothelioma - Your tumor was completely removed by surgery (no visible remaining disease) - You received at least 4 cycles of platinum/pemetrexed chemotherapy around the time of surgery - You are in good overall health (ECOG 0–1) - Your blood counts, liver, kidney, and other organ functions are adequate **You may NOT be eligible if...** - There is visible remaining cancer after surgery - You have an active autoimmune disease (with some exceptions like vitiligo or well-controlled thyroid disease) - You have another active cancer in the last 5 years - You have active HIV, hepatitis B, or hepatitis C - You have had a prior allogeneic stem cell or organ transplant - You have had significant heart problems in the last 3 months - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.